Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 151

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 151
---
 Director                                                                         |
| Michael J. Zelefsky, M.D.  |   |  64 |   | Director                                                                         |

​

Information about our Executive Officers

​

Manuel Litchman, M.D. - President, Chief Executive Officer, Interim Chief Financial Officer and Director

Dr. Litchman has served as our President and Chief
Executive Officer, and as a member of our Board since April 2017. He also became Interim Chief Financial Officer in November 2024. Dr.
Litchman joined us from Arvinas, LLC, where he served as President and Chief Executive Officer. While at Arvinas, Dr. Litchman oversaw
the advancement of the company’s pipeline of protein-degradation therapeutics for the treatment of cancers and other diseases toward
Investigational New Drug applications and secured multi-target discovery collaborations with Merck and Genentech. Prior to Arvinas, Dr.
Litchman spent more than 18 years with Novartis Pharmaceuticals Corporation, where he held positions of increasing responsibility related
to the development of Novartis’ oncology pipeline. Most recently, Dr. Litchman served as Senior Vice President and Executive Global
Program Head, CTL019, Cell & Gene Therapies Unit, where he led a collaboration with the University of Pennsylvania investigating chimeric
antigen receptor modified T cells (“CAR Ts”) directed against CD19 on B cell malignancies. Prior to the CTL019 collaboration,
Dr. Litchman served as Novartis’ Vice President and Head, Oncology Business Development & Licensing. Earlier in his career,
Dr. Litchman was a senior equity analyst at Ursus Capital and directed oncology/immunology clinical research at Hoffmann-La Roche Inc.
Dr. Litchman received his M.D. from Yale University School of Medicine, and his B.A. from Princeton University. He completed his
internal medicine residency and hematology-oncology fellowship at New York-Presbyterian/Weill Cornell Medical Center. Based on Dr. Litchman’s
biotechnology and pharmaceutical industry experience and in-depth understanding of our business, we believe that Dr. Litchman has the
appropriate set of skills to serve as a member of the Board.

Information about our Non-Employee Directors

​

Michael S. Weiss – Chairman of the Board of Directors and Executive Chairman

Mr. Weiss has served as Chairman of our Board
since May 2015 and has also served as our Executive Chairman since January